Choosing SGLT2 Inhibitors vs GLP-1 Receptor Agonists

Evidence-based Management of T2D with ASCVD, CKD, or HFПодробнее

Evidence-based Management of T2D with ASCVD, CKD, or HF

Individualized Glycemic Goals & Choosing Therapy in Type 2 DiabetesПодробнее

Individualized Glycemic Goals & Choosing Therapy in Type 2 Diabetes

ADA EASD Diabetes consensus treatment flowchartПодробнее

ADA EASD Diabetes consensus treatment flowchart

NYSCHP Diabetes Miniseries: Part 1Подробнее

NYSCHP Diabetes Miniseries: Part 1

2022 NICE diabetes updateПодробнее

2022 NICE diabetes update

SGLT2 inhibitors - Diabetes and Heart Failure cured in oneПодробнее

SGLT2 inhibitors - Diabetes and Heart Failure cured in one

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2DПодробнее

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital SettingПодробнее

Protocols for Safe Use of SGLT2i and GLP1RA in the Hospital Setting

James R. Gavin III, MD, PhDПодробнее

James R. Gavin III, MD, PhD

Type 2 Diabetes: The Benefits and Cost-Effectiveness of SGLT2 InhibitorsПодробнее

Type 2 Diabetes: The Benefits and Cost-Effectiveness of SGLT2 Inhibitors

Exploring the Science and Practice of GLP-1 Receptor AgonistsПодробнее

Exploring the Science and Practice of GLP-1 Receptor Agonists

Type 2 Diabetes: New Guidelines and ControversiesПодробнее

Type 2 Diabetes: New Guidelines and Controversies

Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'Подробнее

Prof Melanie Davies - 'Do GLP-1 analogues and SGLT2 inhibitors have a role beyond type 2 diabetes?'

Does SGLT-2 Inhibition Have a Role in the Management of Diabetes?Подробнее

Does SGLT-2 Inhibition Have a Role in the Management of Diabetes?

События